Intense training blocks, illness recovery, or detoxification protocols
Inagawa R, Okada H, Takemura G, Suzuki K, Takada C, Yano H, Ando Y, Usui T, Hotta Y, Miyazaki N, Tsujimoto A, Zaikokuji R, Matsumoto A, Kawaguchi T, Doi T, Yoshida T, Yoshida S, Kumada K, Ushikoshi H, Toyoda I, Ogura S
In T2D, significant apoptotic changes are seen where Bax expression is comparatively higher than Bcl-2 indicating increased apoptotic neutrophils [43]
treat hypoglycaemia with 1520 grams of fast-acting carbohydrate if below 4.0 mmol/L
All use must remain within research-only boundaries - neither compound is approved by the FDA or EMA, BPC-157 was placed on the FDA 503A Category 2 list in 2023, and TB-500 is on the WADA Prohibited List under class S2
Hypothalamic-pituitary communication studies